Aim: We designed a study to evaluate the cardioprotective effect of two soluble epoxide hydrolase (sEH) inhibitors, 1-(1-propanoylpiperidin-4-yl)-3-(4-trifluoromethoxy) phenyl)urea (TPPU) and trans-4-{4-[3-(4-trifluoromethoxyphenyl)-ureido]cyclohexyloxy}benzoic acid (t-TUCB), in ischemia-reperfusion (IR) model.
| INTRODUCTION
Cardiovascular disease is one of the most serious diseases throughout the world in terms of reported deaths and cost of hospitalization. 1, 2 Ischemic heart disease/coronary artery disease (IHD/CAD) is one of the major cardiovascular diseases and results from imbalance between the myocardial supply and demand for oxygenated blood. Myocardial damage such as myocardial infarction is not fully reversible and increases the pressure overload of the heart. The heart can manage limited pressure overload by contracting faster but will fail if pressure overload is not decreased by minimizing myocardial damage and augmenting supply of oxygenated blood. 3, 4 One of the causative factors for deleterious contraction of blood vessels is endothelial dysfunction which is commonly observed in patients with diabetes and hypertension. [5] [6] [7] [8] Endothelial dysfunction is associated with the degree of oxidative stress [ 9, 10 ].
Endothelial dysfunction also plays a role in hypertension. 11 Despite numerous therapeutic approaches for cardiovascular diseases, endothelial dysfunction remains to be a problem. Recent reports indicate the potential utility of sEH inhibitors for cardiovascular diseases.
These molecules relax blood vessels under some conditions 12 and decrease high blood pressure. 13 The sEH metabolizes the arachidonic acid-derived epoxyeicosatrienoic acids (EETs) to less active dihydroxy metabolites. EETs seem to have homeostatic roles in cardiac and renal physiology in addition to being potently antiinflammatory molecules.
Therefore, inhibition of sEH exerts vasodilatory effect by minimizing the degradation of and stabilizing the levels of EETs.
In this study, we evaluated the cardioprotective activity of two structurally different sEH inhibitors, TPPU and t-TUCB ex vivo, using
Langendorff's apparatus where cardiac damage was induced by ischemia and reperfusion. In addition, we expanded to diabetic and hypertensive models to test the hypothesis that inhibition of sEH would be beneficial for cardiac damage induced by IR. These experiments were supported by in vitro assays on isolated blood vessels. Endothelial damage was elicited in thoracic aorta by inducing diabetes and hypertension in Wistar rats. The effect of sEH inhibition was evaluated on endothelial function ex vivo using acetylcholine (ACh) as a marker of endothelial function.
| MATERIALS AND METHODS

| Chemicals and materials
Streptozotocin (Sigma-Aldrich Co., St. Louis, MO, USA), CK-MB kit (Span diagnostic, Surat, Gujarat, India), LDH kit (Span diagnostic, India), ketamine hydrochloride (Neon Labs, Mumbai, Maharashtra, India), xylazine hydrochloride (Indian Immunologicals Ltd., Hyderabad, Telangana, India), and heparin (Gland Pharma Ltd., Hyderabad, Telangana, India)
were purchased. The sEH inhibitors were synthesized as previously reported. 14, 15 Other reagents were of analytical grade.
| Animals
The animal experiment was conducted after obtaining the permis- 
| Induction of hypertension
Hypertension was induced by providing 10% of fructose in drinking water orally for 2 months. The development of hypertension in rats was confirmed by measuring blood pressure using tail cuff apparatus. Data were recorded and saved in a data acquisition system (AD Instrument, Australia 
| Induction of diabetes
| Isolated heart in vitro and ex vivo study
For the in vitro study, rat was given heparin (100 units/rat, ip) prior to anesthesia. After 15 minutes, rat was anesthetized with ketamine hydrochloride (65 mg/kg, ip) and xylazine (10 mg/kg, ip). Heart was isolated and washed in Krebs-Henseleit (K-H) solution saturated with carbogen gas (95% O 2 and 5% CO 2 ) to remove blood. The heart was then mounted on a cannula and perfused with K-H solution gassed with carbogen gas at 37°C at a constant flow rate of 5 mL/minutes by means of peristaltic pump (Masterflex pumps from Cole-Parmer, Vernon Hills, IL, USA) using a modified Langendorff's setup. A fine thread was tied to the apex of the heart and passed through a pulley to the force transducer (MLT500, ADInstruments, Bella Vista, Australia) connected to AD Instrument data acquisition system. Twogram tension was applied to the heart. In the thermostatic chamber, the heart was allowed to equilibrate for 10 minutes. TPPU and t-TUCB were dissolved in PEG400 (30 mg/mL) and then diluted in distilled water to give a true solution. The effect of TPPU and t-TUCB (1 ng-10 μg/100 μL) was observed on heart rate and developed tension after injecting the inhibitor solutions into the latex injection port of modified Langendorff's apparatus under normal conditions of perfusion. 20 This latex injection port was present outside the thermostatic chamber, and just before cannula. Two different concentrations of the sEH inhibitors were injected with the intervals of 5 minutes.
For ex vivo studies, the heart was isolated from rat treated with 
| Estimation of cardiac damage
Activities of LDH and CK-MB in heart perfusate samples were determined for assessing cardiac damage or injury, upon reperfusion.
Samples of the perfusate were collected from the isolated perfused heart at 0-5 minutes and 10-15 minutes of reperfusion in control as well as treatment groups and used for estimation of the enzyme activity. Mean LDH and CK-MB activities were reported.
The LDH activity was determined by monitoring the rate of reduced nicotinamide adenine dinucleotide (NADH) oxidation in the presence of pyruvate. 21, 22 To 2.5 mL of phosphate buffer (100 mM), 1 mL of perfusate and 100 μL of NADH (2.5 mg/mL of phosphate buffer) were added. The mixture was allowed to stand for 20 minutes.
After transferring it into a cuvette, the absorbance was measured using a UV-visible spectrophotometer (SHIMADZU, UV-16100, Japan)
at 340 nm for 30 sec after the addition of 100 μL of sodium pyruvate (22.7 mM) solution (the initial reading at zero time), and the rate of change in extinction was recorded every minute for 3 minutes.
Calculation:
where ΔE 340/min=average change in absorbance/min; 3.7=total reaction volume expressed in mL; 1000=conversion of units/mL to units/l; 1=sample volume in mL; 6.3=mM absorptivity of NADH.
CK-MB activity in perfusate was estimated by using CK-MB lab kit (Span Diagnostics, India) according to manufacturer instruction.
Briefly, to 500 μL of working reagent solution, 25 μL of anti-CK-MM reagent was added, and the solution was mixed thoroughly. Fifty microliter of perfusate containing CK-MB was added and vortexed. The mixture was aspirated immediately into Semi-Auto Analyzer (ARTOS, India) at 37°C, and with 600 seconds delay time absorbance was measured at 340 nM every minute starting from 0 to 3 minute, and change in absorbance was calculated. 23 where, ΔE/340 nm=average change in absorbance at 340 nm.
| In vitro and ex vivo blood vessel study
The thoracic aorta of anesthetized rat was isolated, washed in K-H solution maintained at 37°C and then mounted between two steel hooks in a four-channel organ bath containing 20 mL K-H solution.
This chamber was continuously aerated with carbogen gas. The aorta was stretched to 2 g tension and washed with K-H solution 4 times within 1 hour. After stabilization of the aorta, different concentrations (1 ng/mL-100 μg/mL, final concentration) of sEH inhibitors were added to organ bath, and possible contractile effect of sEH inhibitors were evaluated.
For evaluating possible relaxant effect, first the aorta was contracted with submaximal dose of adrenergic α1 receptor agonist, phenylephrine, and then lisinopril, metformin, TPPU, or t-TUCB were added separately at increasing concentrations, and relaxant effects were monitored.
To evaluate the effect of sEH inhibitors in diabetes-induced en- 
| Statistical analysis
Data are expressed as mean ± SEM. The results related to the heart study were subjected to a one-way analysis of variance (ANOVA), followed by Tukey's multiple comparison post hoc test. The results of the aorta study were subjected to two-way ANOVA followed by Bonferroni's post hoc test for statistical evaluation. GraphPad Prism (version: 5.03) statistical program was used for statistical calculation and generation of the graphs.
| RESULTS
Rats which received STZ displayed expected increase in the level of glucose in blood. Normal rats had 110±10 mg/dL blood glucose, LDH activity = ΔE340∕min × 3.7 × 1000 1 × 6.3 units/l CK − MB activity = ΔE 340nm × 3697.5(Kinetic factor)units/l
| Treatment with sEH inhibitors minimize decrease in heart rate
A hallmark of IR injury in both rodents and men is a decrease in heart rate due to reduced contractility. Ischemia-reperfusion injury expectedly led to a significant decrease in mean heart rate (244/ minute, without IR vs 198/minute, after IR; P<.05) in normal rats.
Vehicle (PEG400 in water) did not have any effect on heart rate. mean heart rate. Overall, both TPPU and t-TUCB significantly (P<.001) reduced the IR-driven decrease in heart rate in the isolated hearts from normal, hypertensive, and diabetic rats ( Figure 1 ).
These data suggest inhibition of sEH promotes the maintenance of normal heart rate.
| Treatment with sEH inhibitors minimize increase in resting tension
Mean resting tension, a parameter of muscle contractility in- 
| Treatment with sEH inhibitors minimize decrease in developed tension
As would be expected from IR injury, mean developed tension was significantly (6 g, pre-IR vs 5 g, post-IR; P<.05) lower after IR. this IR-driven decrease in developed tension (Figure 3 ).
| Treatment with sEH inhibitors decrease cardiac damage
A major consequence of IR injury is cardiac damage, and this was evident in hearts subjected to IR throughout this study. Activities of LDH and CK-MB were higher in perfusate samples of hearts from hypertensive and diabetic rats in comparison to normal rats treated with vehicle (P<.05). This implies that hypertension and diabetes increase susceptibility to myocardial infarction, a well-established outcome.
Treatment with sEH inhibitors significantly decreased (P<.001) activities of LDH and CK-MB in perfusate of hearts ( Figure 4 ) demonstrating a cardioprotective effect.
| Treatment with sEH inhibitors decreases endothelial dysfunction
In addition to the observed cardioprotective effects on isolated hearts, we tested if the inhibitors of sEH modulate the contractility of the F I G U R E 1 Treatment with sEH inhibitors reduces IR-induced decrease in the heart rate. (A) Treatment with vehicle did not change heart rate after IR injury, whereas treatment with sEH inhibitors minimized a significant decrease (***P<.001) in heart rate in comparison to normal control rats treated with water. (B) Hypertension did not decrease heart rate significantly after IR. Treatment with lisinopril and both doses of sEH inhibitors significantly reduced (***P<.001) the hypertension-driven decrease in heart rate in comparison to untreated hypertensive rats. (C) Diabetes significantly decreased heart rate ( c P<.001) after IR in comparison to normal rats treated with water. Treatment with metformin and both doses of sEH inhibitors significantly reduced (***P<.001) the diabetes-driven decrease in heart rate in comparison to untreated diabetic rats. Metformin was more effective (*P<.05) than t-TUCB (0.1 mg/kg). Data are presented as mean ± SEM of six observations. One-way ANOVA followed by Tukey's multiple comparison test was used for statistical calculation 
P<.01) developed tension after IR in
comparison to normal rats treated with water, and treatment with metformin and both sEH inhibitors significantly reduced (**P<.01) diabetesdriven decrease in developed tension in comparison to untreated diabetic rats. Metformin (500 mg/kg) was more effective (*P<.05) than t-TUCB (0.1 mg/kg). Data are presented as mean ± SEM of 5-6 observations. One-way ANOVA followed by Tukey's multiple comparison test was used for statistical calculation After administration of 0.1 and 0.3 mg/kg doses, blood levels of TPPU reach much higher than its IC 90 value on recombinant rat sEH.
24,25
In addition, here we maintained the animals on daily doses of sEH inhibitors which should sustain a high degree of inhibition. In ex vivo experiments, we measured changes in multiple important parameters to normal rats treated with water. Treatment with metformin (500 mg/kg) (***P<.001) and both doses of sEH inhibitors significantly reduced (**P<0.01) diabetes-induced increase in the activity of CK-MB in comparison to untreated diabetic rats. TPPU (***P<.001) and t-TUCB (**P<.01) dose dependently protected heart. Metformin at 500 mg/kg was better effective (*P<0.05) than TPPU (0.1 mg/kg) and t-TUCB (both doses). Data are presented as mean ± SEM of six observations. One-way ANOVA followed by Tukey's multiple comparison test was used for statistical calculation. *** ** ** *** *** ** ** *** *** *** *** *** ** ** *** *** *** *** *** * *** ** of cardiovascular function. The sEH inhibitors did not alter baseline heart rate and developed tension. This is consistent with previous publications.
Effect of IR on cardiac function was evaluated by quantifying heart rate, resting tension, and developed tension. A significant decrease in heart rate and developed tension and an increase in resting tension after IR injury precede pathological changes in a failing heart. Resting tension represents the force experienced by heart, whereas developed tension represents work performed by heart. Here consistent with earlier work, we observed that hypertension and diabetes increase workload of heart and decrease performance of the heart. Although hypertension and diabetes did not increase resting tension significantly in this model, the antihypertensive (lisinopril) and antidiabetic (metformin) medicines significantly minimized hypertension-and diabetesdriven increase in resting tension respectively. This signifies the role of hypertension and diabetes on increasing resting tension in IR model. Lisinopril and metformin reduced hypertension and diabetes-induced decrease in developed tension. These findings are in line with the impact of hypertension and diabetes on cardiac function. However, treatment with the sEH inhibitors reversed these pathological changes in cardiac function. The increase in the activity of LDH and CK-MB in the organ perfusate after ischemia is direct evidence of cardiac damage.
Higher levels of cardiac damage were observed in the hearts of rat with diabetes and high blood pressure in comparison to normal and healthy rats. Similarly, endothelial dysfunction was also observed in the aorta of rat with diabetes or hypertension in comparison to the normal rat.
Prophylactic treatment with sEH inhibitors at 100 and 300 μg/kg daily dose for 4 weeks significantly protected the heart from cardiac injury and aorta from endothelial dysfunction.
The inhibitors of sEH have been reported to decrease hypertension in numerous animal models including angiotensin-induced, saltsensitive, and maternally fructose-fed hypertension in addition to genetically hypertensive Goto-Kakizaki rats. [26] [27] [28] [29] [30] The antihypertensive effect of sEH inhibitors is thought to be mediated through increasing the levels of epoxy fatty acids, more specifically the EETs and epoxydocosapentaenoic acids derived from DHA. 24, 30, 31 A stable synthetic analog of EET also decreased angiotensin-induced hypertension. 32 Typically, cardiac damage is more evident in hearts of hypertensive rats than healthy rats, and lisinopril, an inhibitor of angiotensin converting enzyme, reduces cardiac damage in hypertensive animals. We observed the same phenomena here and inhibition of sEH was highly effective in reversing this damage. These observations suggest a fundamental role for the EETs and other epoxy fatty acids in maintaining homeostasis and reducing cardiac damage.
Cardiovascular abnormalities are reported in patients with diabetes. Heart rates of diabetics are reported to be decreased in comparison to nondiabetics. 33 Data from a Finnish population-based study suggest that patients with diabetes are at a significant risk of developing myocardial infarction in comparison to nondiabetic patients.
34
Myocardial infarction leads to congestive heart failure. The risk of congestive heart failure and coronary artery disease is highest in diabetes as suggested by the Framingham study. 35 The American Heart
Association recognizes a significant risk of cardiovascular disease in diabetes and considers diabetes as a cardiovascular disease. 36 Here, cardiac damage was expectedly more significant in hearts of diabetic rats compared to healthy rats. As would be expected from earlier body of work, metformin reduced cardiac damage. Furthermore, inhibition of sEH largely reduced cardiac damage in hearts of diabetic rats suggesting that sEH inhibitors are cardioprotective compounds.
Inhibition of sEH and genetic deletion are reported to decrease hyperglycemia, promote insulin secretion, and reduce islet apoptosis. 37 The cardioprotective effect of sEH inhibitors in diabetic rats could be due to decrease in hyperglycemia and apoptosis of islets, and increase in the secretion of insulin. [37] [38] [39] However, given that similar effects are observed in hypertensive animals, it is likely that the sEH inhibitors have a direct protective effect.
Endothelial dysfunction is an important hallmark of both hypertension and diabetes. In this study, we evaluated the endothelial dysfunction using responses of the aorta to relaxation by ACh as a marker of endothelial function. We observed an increase in endothelial dysfunction with diabetes and hypertension, and treatment with sEH inhibitors ameliorated the endothelial dysfunction. Endothelial dysfunction increases the propensity of eventual myocardial damage, and improvement of endothelial function in diabetes 40, 41 and hypertension 42 minimizes the possibility of myocardial damage. Thus, improvement of endothelial function could be the basis of the cardioprotective effects of sEH inhibitors in ischemia-reperfusion injury both in diabetic and hypertensive rats.
Earlier, we reported the cardioprotective effect of t-TUCB at 3-30 mg/kg against isoproterenol-induced myocardial infarction in normal rats. 43 In this study, we demonstrate that both t-TUCB and TPPU protect hearts at very low doses (ie, 0.1-0.3 mg/kg). More importantly, the sEH inhibitors ameliorated cardiac damage in both hypertension and diabetic models. One mechanism related to IRinduced cardiac damage seems to be endoplasmic reticulum (ER) stress. [44] [45] [46] [47] The ER is a complex organelle on which most protein syn- In cases where these unfolding protein response elements (UPREs:
PERK, IRE1 and ATF6) are unable to overcome the stress, apoptotic pathways are activated. [48] [49] [50] [51] [52] [53] Chemical inhibition of sEH and genetic deletion has been demonstrated to decrease ER stress. [53] [54] [55] The cardioprotective effect of sEH inhibitors in this model could therefore be due to mitigation of ER stress. Another possible mechanism for these effects could be the known decrease in inflammation by the inhibitors of sEH. Inflammatory responses are reported in IR with increase in the levels of TNFα and IL-6. 56, 57 The minimization of cardiac damage also could be due to elevation of antiinflammatory epoxy fatty acids and decrease in inflammatory mediators by sEH inhibitors. 25, 58, 59 A limitation of this research is that we did not quantify the effect Echocardiography and in vivo ischemia-reperfusion injury also would have provided stronger data.
| CONCLUSIONS
The sEH inhibitors minimize cardiovascular damage in heart from normal, diabetic, and hypertensive rats due to ischemia-reperfusion injury suggesting the importance of epoxy fatty acids as chemical mediators in cardiac health. Therefore, sEH inhibitors such as TPPU and t-TUCB can be useful in the ischemia-reperfusion-related cardiac damage. These findings could be applicable to both human and companion animals suffering from cardiac pathology. Treatment with both the inhibitors ameliorated endothelial dysfunction. Further studies are warranted for elucidating mechanism of cardiac protection.
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